Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Xdemvy Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PMN.291

    Clinical Policy: Lotilaner (Xdemvy)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PMN.291 alerts

    Get alerted when Policy CP.PMN.291 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Xdemvy ophthalmic solution for Demodex blepharitis and other requested indications in commercial, marketplace/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lotilaner (Xdemvy)
    Policy CodePolicy CP.PMN.291
    Change TypeMaterial update
    Effective DateDecember 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that the member meets all applicable approval criteria, including diagnosis, specialist prescriber or consultation, age, and quantity requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a requirement that Xdemvy be prescribed by or in consultation with an optometrist or ophthalmologist.

    The policy added the health insurance marketplace/ICHRA line of business.

    18 yearsMinimum age
    1 bottle/6 weeksMaximum quantity
    6 weeksInitial approval
    1 drop BIDDosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not permittedReauthorization

    Coverage Criteria

    Initial Approval Criteria — Demodex Blepharitis

    Covered when all of the following are met:

    Initial approval for Demodex blepharitis

    • The member has a diagnosis of Demodex blepharitis.
    • Xdemvy is prescribed by or in consultation with an optometrist or ophthalmologist.
    • The member is at least 18 years old.Age ≥18 years
    • The request does not exceed 1 bottle per 6 weeks.≤1 bottle per 6 weeks

    Initial Approval Criteria — Other Diagnoses or Indications

    Other diagnoses or indications must meet criterion 1 or criterion 2:

    Other diagnoses or indications

    • Criterion 1 — Recent label change

      • Within the last 6 months, the drug has undergone a label change, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
      • Refer to the applicable no-coverage or non-formulary policy based on whether the drug is on the formulary or Medicaid PDL and the member's line of business.

        Applicable policies include CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, and CP.PMN.16, as applicable.

    • Criterion 2 — Off-label use

      • The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the diagnoses or indications for which coverage is not authorized.

    Continued Therapy — Demodex Blepharitis

    Reauthorization is not permitted:

    Continued therapy for Demodex blepharitis

    • Members requesting additional therapy must meet the initial approval criteria.
    • Reauthorization is not permitted.Not applicable

    Continued Therapy — Other Diagnoses or Indications

    Other continued diagnoses or indications must meet criterion 1 or criterion 2:

    Other continued diagnoses or indications

    • Criterion 1 — Recent label change

      • Within the last 6 months, the drug has undergone a label change, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
      • Refer to the applicable no-coverage or non-formulary policy based on whether the drug is on the formulary or Medicaid PDL and the member's line of business.

        Applicable policies include CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, and CP.PMN.16, as applicable.

    • Criterion 2 — Off-label use

      • The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the diagnoses or indications for which coverage is not authorized.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety supports review under the applicable off-label-use policy or evidence of coverage documents. The applicable off-label policy is CP.CPA.09 for commercial members, HIM.PA.154 for health insurance marketplace/ICHRA members, and CP.PMN.53 for Medicaid members.

    Provider Requirements and Decision Rules

    Prior Authorization

    Required Approval Criteria

    For Demodex blepharitis, the request must document that all initial approval criteria are met. Approval is limited to 6 weeks.

    • Diagnosis of Demodex blepharitis
    • Prescribed by or in consultation with an optometrist or ophthalmologist
    • Member is age ≥ 18 years
    • Request does not exceed 1 bottle per 6 weeks
    Note

    Other Indications Require Alternate Policy Review

    Requests for other diagnoses or indications, including continued-therapy requests, require review under the applicable alternate policy. Select the pathway based on the drug’s formulary or PDL status and whether the use is addressed by a recent label change or is otherwise off-label.

    • For a label change within the last 6 months not yet reflected in this policy: use the applicable no-coverage policy for formulary or PDL drugs—CP.CPA.190 (commercial), HIM.PA.33 (health insurance marketplace/ICHRA), or CP.PMN.255 (Medicaid).

    Clinical Background

    Lotilaner ophthalmic solution (Xdemvy) is an ectoparasiticide indicated by the FDA for the treatment of Demodex blepharitis. This policy addresses prior authorization and medical-necessity coverage for Xdemvy, limiting covered initial treatment to members who are at least 18 years old and whose prescription is provided by or in consultation with an optometrist or ophthalmologist.

    Definitions

    Definitions
    FDAFood and Drug Administration

    Initial Therapy Criteria

    Initial Therapy — Demodex Blepharitis

    Demodex blepharitis must meet all criteria:

    Demodex blepharitis initial therapy

    • The member has a diagnosis of Demodex blepharitis.
    • Xdemvy is prescribed by or in consultation with an optometrist or ophthalmologist.
    • The member is at least 18 years old.Age ≥18 years
    • The request does not exceed 1 bottle per 6 weeks.≤1 bottle per 6 weeks

    Continuation Therapy Criteria

    Demodex Blepharitis Continuation

    Reauthorization is not permitted:

    Demodex blepharitis continuation

    • Members requesting additional therapy must meet the initial approval criteria.
    • Reauthorization is not permitted.Not applicable

    Other Indications Continuation

    Other continued diagnoses or indications must meet criterion 1 or criterion 2:

    Other continued indications

    • Criterion 1 — Recent label change

    Quantity and Supply Limits

    Quantity Limits
    Xdemvy maximum quantity1 bottle per 6 weeks
    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lotilaner (Xdemvy)
    Policy CodePolicy CP.PMN.291
    Change TypeMaterial update
    Effective DateDecember 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that the member meets all applicable approval criteria, including diagnosis, specialist prescriber or consultation, age, and quantity requirements.
    SourceLink
    On This Page
    Coverage CriteriaProvider Requirements and Decision RulesClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaQuantity and Supply Limits
    Criterion 1 does not apply.
  1. Refer to the applicable off-label use policy for the member's line of business.

    Applicable policies include CP.CPA.09, HIM.PA.154, and CP.PMN.53, as applicable.

  2. Criterion 1 does not apply.
  3. Refer to the applicable off-label use policy for the member's line of business.

    Applicable policies include CP.CPA.09, HIM.PA.154, and CP.PMN.53, as applicable.

  4. For a label change within the last 6 months not yet reflected in this policy involving a non-formulary or non-PDL drug: use the applicable non-formulary policy—CP.CPA.190 (commercial), HIM.PA.103 (health insurance marketplace/ICHRA), or CP.PMN.16 (Medicaid).
  5. If the requested use is not listed under Section III and the recent-label-change pathway does not apply, use the applicable off-label policy—CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace/ICHRA), or CP.PMN.53 (Medicaid).
  6. Documentation Required

    Clinical Documentation Required

    The provider must submit documentation supporting that the member has met all applicable approval criteria before authorization can be considered.

    • Office chart notes
    • Laboratory results
    • Other relevant clinical information supporting the diagnosis, prescribing requirements, age, dosing, and requested quantity
    Denial Risk

    Initial Criteria Not Met

    An initial request may be denied when any required criterion is not met or cannot be supported by the submitted documentation.

    • Demodex blepharitis diagnosis is not established
    • The prescriber is not an optometrist or ophthalmologist and there is no qualifying consultation
    • Member is younger than 18 years
    • Request exceeds 1 bottle per 6 weeks
    Denial Risk

    No Reauthorization for Demodex Blepharitis

    Reauthorization is not permitted for Demodex blepharitis. Any additional request must be evaluated against the initial approval criteria.

    • Approval duration: 6 weeks
    • Continued-therapy approval duration: Not applicable
    Documentation Required

    Unaddressed Non-FDA-Approved Indication

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless the request includes sufficient documentation of efficacy and safety under the applicable off-label use policy or evidence of coverage documents.

    • Use CP.CPA.09 for commercial members, HIM.PA.154 for health insurance marketplace/ICHRA members, or CP.PMN.53 for Medicaid members.
    • Submit documentation supporting efficacy and safety, or applicable evidence of coverage documents.

    Initial Therapy — Other Indications

    Other diagnoses or indications must meet criterion 1 or criterion 2:

    Other diagnoses or indications

    • Criterion 1 — Recent label change

      • Within the last 6 months, the drug has undergone a label change, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
      • Refer to the applicable no-coverage or non-formulary policy based on whether the drug is on the formulary or Medicaid PDL and the member's line of business.

        Applicable policies include CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, and CP.PMN.16, as applicable.

    • Criterion 2 — Off-label use

      • The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the diagnoses or indications for which coverage is not authorized.
      • Criterion 1 does not apply.
      • Refer to the applicable off-label use policy for the member's line of business.

        Applicable policies include CP.CPA.09, HIM.PA.154, and CP.PMN.53, as applicable.

    Within the last 6 months, the drug has undergone a label change, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
  7. Refer to the applicable no-coverage or non-formulary policy based on whether the drug is on the formulary or Medicaid PDL and the member's line of business.

    Applicable policies include CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, and CP.PMN.16, as applicable.

  8. Criterion 2 — Off-label use

    • The requested use, such as the diagnosis, age, or dosing regimen, is not specifically listed under the diagnoses or indications for which coverage is not authorized.
    • Criterion 1 does not apply.
    • Refer to the applicable off-label use policy for the member's line of business.

      Applicable policies include CP.CPA.09, HIM.PA.154, and CP.PMN.53, as applicable.